Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
There is no change in the price for Pacira Pharmaceuticals today.
Our community is currently high on Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 26 € shows a positive potential of 28.71% compared to the current price of 20.2 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.000% | 3.061% | 4.663% | -12.174% | -6.481% | -44.809% | -64.248% |
| Rockwell Medical Inc. | - | -0.740% | 3.871% | -19.095% | 18.995% | -49.243% | -91.431% |
| Twist Bioscience Corp | -3.020% | -6.175% | 4.554% | 25.023% | 46.750% | 222.828% | -63.180% |
| Savara Inc. | -0.180% | 4.205% | 4.205% | 112.863% | -6.019% | 217.261% | 205.583% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat